Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $19.4 million.

  • Ptc Therapeutics' Share-based Compensation fell 166.54% to $19.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.3 million, marking a year-over-year decrease of 83.37%. This contributed to the annual value of $74.6 million for FY2024, which is 2658.61% down from last year.
  • According to the latest figures from Q3 2025, Ptc Therapeutics' Share-based Compensation is $19.4 million, which was down 166.54% from $18.5 million recorded in Q2 2025.
  • Ptc Therapeutics' Share-based Compensation's 5-year high stood at $29.4 million during Q2 2023, with a 5-year trough of $16.5 million in Q4 2023.
  • For the 5-year period, Ptc Therapeutics' Share-based Compensation averaged around $23.5 million, with its median value being $25.7 million (2021).
  • In the last 5 years, Ptc Therapeutics' Share-based Compensation surged by 6890.28% in 2021 and then crashed by 3962.84% in 2023.
  • Over the past 5 years, Ptc Therapeutics' Share-based Compensation (Quarter) stood at $26.2 million in 2021, then grew by 4.22% to $27.3 million in 2022, then tumbled by 39.63% to $16.5 million in 2023, then increased by 4.43% to $17.2 million in 2024, then rose by 12.69% to $19.4 million in 2025.
  • Its Share-based Compensation was $19.4 million in Q3 2025, compared to $18.5 million in Q2 2025 and $18.1 million in Q1 2025.